



**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW




Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffery T. Helvey  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincenzo L. Capuano  
Albert J. Fasulo II  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaton  
Reginald D. Lucas  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn Prengaman  
Jane Shershenovich  
Lawrence J. Carroll  
George S. Bardmesser  
Rodney G. Maze

**Registered Patent Agents\***  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Robert A. Schwartzman  
Jason D. Eisenberg  
John J. Figueroa

**Senior Counsel**  
Samuel L. Fox  
Kenneth C. Bass III  
Lisa K. Dunner



\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas  
\*Practice Limited to  
Federal Agencies

September 11, 2002

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/826,206; Filed: April 5, 2001  
For: **Ketogulonigenium Shuttle Vectors**  
Inventors: John D'Elia  
Our Ref: 1533.1100001/MAC/DJN

**WRITER'S DIRECT NUMBER:**  
(202) 371-2544  
**INTERNET ADDRESS:**  
MCIMBALA@SKGF.COM

Art Unit 1652

**RECEIVED**

SEP 16 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement;
2. Form PTO-1449 listing the fifty-four (54) cited documents;
3. Copies of the fifty-four (54) cited documents as listed on Form PTO-1449; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Michele A. Cimbala*

Michele A. Cimbala  
Attorney for Applicants  
Registration No. 33,851

MAC/DJN  
Enclosures

SEP 16 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

John D'Elia

Appl. No. 09/826,206

Filed: April 5, 2001

For: **Ketogulonigenium Shuttle Vectors**

Confirmation No. 2584

Art Unit: 1652

Examiner: *To Be Assigned*

Atty. Docket: 1533.1100001/MAC/DJN

#10  
JGJ  
9/17/02

**Second Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on April 12, 2002, in connection with the above-captioned application. A copy of each document is also provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicant's undersigned representative submits the following, in regard to non-English language documents AN1, AO1, AP1, AL2, AM2, AL3, AN3, AP3, AL4, AM4, AN4, AR12 and AS12 cited on Form PTO 1449:

Document **AN1**, patent JP 41-159 is in the Japanese language. An English language translation of document AN1 is attached as document **AT13**.

Document **AO1**, patent JP 41-160 is in the Japanese language. An English language translation of document AO1 is attached as document **AR14**.

Document **AP1**, patent JP 41-5907 is in the Japanese language. An English language translation of document AP1 is attached as document **AS14**.

Document **AL2**, U.S.S.R. patent 526,660 is in the Russian language. An English language abstract of document AL2 is attached as document **AT14**. Document AL2 is believed to describe the derivation of strain *Pseudomonas fluorescens* 806 from strain *Pseudomonas fluorescens* C-4. The document is further believed to describe the production of 2-keto-L-gulonic acid from sorbose by *Pseudomonas fluorescens* 806.

Document **AM2**, patent JP 59-113896 is in the Japanese language. An English language abstract of document AM2 is attached as document **AT15**. Document AM2 is believed to describe the preparation of fermentation methods and collection of pyrroloquinoline quinone (PQQ) by microorganisms.

Document **AL3**, patent EP 0 276 832 A2 is in the German language. An English language abstract of document AL3 is attached as document **AR16**. Document AL3 is believed to describe the production of 2-keto-L-gulonic acid from L-sorbose by cultivating an appropriate recombinant bacterium, preferably formed by transposon mutagenesis, in a medium containing L-sorbose.

Document **AN3**, patent JP 3-294281 is in the Japanese language. An English language abstract of document AN3 is attached as document **AS16**. Document AN3 is believed to describe the production of oxamzolopyrroloquinolines by microorganisms.

Document **AP3**, patent CN 1,081,470 A, is in the Chinese language. An English language abstract of document AP3 is attached as document **AR15**. Document AP3 is believed to describe an improved method of production of 2-keto-L-gulonic acid by mixed bacterial cultures.

Document **AL4**, patent JP 7-67673 is in the Japanese language. An English language abstract of document AL4 is attached as document **AT16**. Document AL4 is believed to describe the production of 2-keto-L-gulonic acid by a *Pseudogluconobacter saccharoketogenes* strain.

Document **AM4**, patent JP 7-250671 is in the Japanese language. An English language abstract of document AM4 is attached as document **AS15**. Document AM4 is believed to describe the production of 2-keto-L-gulonic acid by a *Pseudomonas* strain in an L-sorbose containing medium.

Document **AN4**, patent JP 8-245702 is in the Japanese language. An English language abstract of document AO4 is attached as document **AR17**. Document AN4 is believed to describe the production of a high molecular weight lipopolysaccharide from microorganisms, especially from the genus *Pantoea*.

Document **AR12**, Yin, G.-L., *et al.*, (1980) is in the Chinese language. An English language translation of document AR12 is attached as document **AR13**.

Document **AS12**, Yin, G.-L., *et al.*, (1981) is in the Chinese language. An English language translation of document AS12 is attached as document **AS13**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala  
Attorney for Applicants  
Registration No. 33,851

Date: 9/11/02

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600